Cargando…
Emerging drugs for partial-onset epilepsy: a review of brivaracetam
There are more than 12 new antiepileptic drugs approved in the last 2 decades. Even with these newer agents, seizure remission is still unachievable in around 30% of patients with partial-onset seizures (POS). Brivaracetam (BRV) is chemically related to levetiracetam (LEV) and possesses a strong bin...
Autores principales: | Gao, Lan, Li, Shuchuen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863588/ https://www.ncbi.nlm.nih.gov/pubmed/27217762 http://dx.doi.org/10.2147/TCRM.S90127 |
Ejemplares similares
-
New developments in the management of partial-onset epilepsy: role of brivaracetam
por: Coppola, Giangennaro, et al.
Publicado: (2017) -
Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies
por: Ben-Menachem, Elinor, et al.
Publicado: (2016) -
Brivaracetam: a novel antiepileptic drug for focal-onset seizures
por: Stephen, Linda J., et al.
Publicado: (2017) -
Profile of brivaracetam and its potential in the treatment of epilepsy
por: Ferlazzo, Edoardo, et al.
Publicado: (2015) -
Brivaracetam in the treatment of epilepsy: a review of clinical trial data
por: Feyissa, Anteneh M
Publicado: (2019)